Renée Nicole Wagner, PhD. completed her broad education at the MODUL hotel and tourism school in Vienna and her studies at the University of Vienna with a doctorate in political science. Various postgraduate studies on the topic of “Economics and sustainability in tourism” as well as specialized trainings around the topic of ESG have always accompanied her in here entire career.
Renée is an ESG expert with passion, coming from the international hospitality field. Currently working for Orascom Hotels Management – one of the biggest hotel owners and operators in the MENA region, with more than 8,000 guestrooms dispersed across Egypt, Oman the UAE, Montenegro and Switzerland.
Passionate Hotelier, Goal Oriented Leader, Luxury Experience Specialist.
Dedicated and innovative hotelier, I am passionate about delivering unparalleled luxury experiences to guests. My career has defined my steadfast commitment to excellence, focus on guest satisfaction and development of high – performing teams.
Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation and member of the Executive Team at MMS, leads the global technical, medical and scientific functions. She has more than 20 years of experience in clinical research, including career highlights at the Mayo Clinic and Pfizer, prior to joining MMS.
Michelle’s long tenure in the data service area and commitment to excellence, fosters a culture across our global offices that attracts the best talent. Her global operational teams are responsible for all elements of clinical trial data strategies and tech-enabled services, including specialized expertise in all data and summarization steps leading to successful NDA submissions globally. Michelle established a Center of Excellence within the global operational teams that bring value beyond the deliverable, emphasizing strong science and process. Metrics and a strong emphasis on service delivery methodology drive the organization. Her teams lend their expertise to client sponsors ensuring the highest level of customer satisfaction and return on their investment.
Amanda Haupt is the Base Editing Business Unit Manager at Revvity. During her years here she has contributed as an R&D Scientist to the company’s portfolio of gene editing reagents. Today, Amanda supports commercialization of Revvity’s Pin-point™ base editing technology.
Benjamin is the Product Manager for the LentiBOOST™ technology at Revvity Gene Delivery, formerly SIRION Biotech. In this role, he maintains close connections with users, partners, and licensees who employ the technology in clinical trials. Benjamin collaborates with all relevant internal and external stakeholders to support the primary goal of making this technology accessible to scientists and, ultimately, to patients. He holds a Master of Science degree in Biology, with a focus on Microbiology and Medical Biology.
Janina Haar is a trained virologist and molecular biologist who holds a PhD from the German Cancer Research Center (DKFZ) and Ruperto Carola University of Heidelberg. After completing her PhD, Janina joined the laboratory of Prof. Dirk Grimm as a Postdoc where she was the leading scientist within an industry collaboration aiming at the development of improved liver-tropic AAV capsids for hemophilia treatment. She transitioned to industry for a second Postdoc at Boehringer Ingelheim where she focused on the optimization of inducible gene expression cassettes for AAV-based gene therapy. Subsequently, Janina worked for Vector BioPharma AG in Basel as Senior Scientist developing adenoviral vectors for immuno-oncology applications and further exploring regulatable gene therapies. Janina joined Revvity in April 2024, where she is currently leading the laboratory team at the Heidelberg site of Revvity Gene Delivery and supporting our collaborations for AAV-based gene therapy development.
Michelle is the Head of Cell and Gene Therapy at Revvity. In this role, Michelle steers the strategic direction and influences how Revvity showcases its diverse array of CGT capabilities, across products, contracted services and technology licensing, to facilitate the advancement and launch of innovative cell and gene therapies. Michelle has a PhD in mycology and a Graduate Diploma in Science and Technology Commercialization from the University of Adelaide. She was previously manager of Revvity’s base editing business and our next generation sequencing product portfolio.
